Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit
Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who had detectable circulating ...
Apr 29, 2025
0
0